Maternal autoimmune disease and the placental journey of antibodies

Many women of reproductive age live with autoimmune conditions such as systemic lupus erythematosus, Sjögren syndrome, immune thrombocytopenia, or myasthenia gravis. Pregnancy adds a unique biological layer because maternal immunoglobulin G crosses the placenta and shapes fetal immune development. The same protective mechanism that arms the newborn against early infections can occasionally deliver pathogenic antibodies capable of disturbing fetal cardiac, haematological, or neuromuscular function.

For clinicians across Australia, New Zealand, and the broader Asia-Oceania region, understanding the kinetics of this transfer influences how they counsel families and design surveillance pathways. Scientific gatherings such as the FAOPS 2020 congress, originally planned for Tokyo alongside PREBIC AA 2020, dedicated session time to maternal-fetal immunology because the topic bridges rheumatology, obstetrics, and neonatal medicine. The cancellation in April 2020 did not diminish the importance of these conversations, which continue to shape regional clinical practice.

Transplacental IgG transfer in plain language

The placenta is not a passive sieve. Active transport mediated by the neonatal Fc receptor, often abbreviated FcRn, selectively escorts IgG molecules from maternal blood into the fetal circulation. IgG1 and IgG3 cross most efficiently, while IgG2 and IgG4 move more slowly, and the process accelerates after 16 to 20 weeks of gestation. By the time a baby is born at term, fetal IgG levels usually exceed maternal concentrations, a phenomenon obstetricians sometimes describe as active placental immunity.

The clinical relevance lies in antibody specificity. Pathogenic autoantibodies travel along the same FcRn pathway as protective antibodies, so any maternal IgG directed against fetal antigens can theoretically reach the fetus. This is why neonatologists pay close attention to a mother's diagnosis, antibody titre, and treatment history. The Australian and New Zealand Neonatal Network has long documented how prenatal exposures influence admission rates to special care nurseries across the country, and placental antibody transfer remains a recurring theme in its annual reports.

Conditions where placental antibody transfer matters

Several well-characterised autoimmune diseases carry neonatal implications when autoantibodies cross the placenta. Anti-SSA/Ro and anti-SSB/La antibodies, found in lupus and Sjögren syndrome, are associated with neonatal lupus and congenital heart block, the latter sometimes requiring pacing soon after birth. Antiplatelet antibodies in immune thrombocytopenia can produce fetal or neonatal thrombocytopenia, with implications for delivery planning and bleeding risk.

Other conditions include myasthenia gravis, where anti-acetylcholine receptor antibodies may cause transient neonatal myasthenia with poor feeding and hypotonia in the first days of life. Graves disease, driven by stimulating antibodies against the TSH receptor, can lead to neonatal thyrotoxicosis with tachycardia, irritability, and poor weight gain. Less common but noteworthy is pemphigus, where antidesmoglein antibodies occasionally produce transient blistering in the newborn. Each condition carries a characteristic timing pattern that informs clinical vigilance.

Australian realities for mothers and clinicians

Australia's maternity landscape combines world-class tertiary centres with vast distances and culturally diverse populations. In metropolitan hubs such as Sydney, Melbourne, Brisbane, Perth, and Adelaide, mothers with autoimmune disease are typically managed through multidisciplinary clinics that link rheumatology, maternal-fetal medicine, and neonatology. Tertiary hospitals affiliated with universities host fetal cardiology and high-risk pregnancy services, while regional centres in Cairns, Townsville, Darwin, and Hobart coordinate care via telehealth and visiting specialists.

The public health system, anchored by Medicare and the Pharmaceutical Benefits Scheme, allows most women to access essential medications, including hydroxychloroquine, prednisolone, and azathioprine, at subsidised prices. PBS listings for newer biologics during pregnancy remain narrower, which sometimes pushes clinicians and families toward shared decision-making about risk and benefit. RANZCOG statements and the Australian Society of Obstetric Medicine provide local guidance that complements international rheumatology recommendations and reflects Australian prescribing realities.

Remote and rural mothers, including those in the Kimberley, the Pilbara, central western Queensland, and parts of the Northern Territory, face additional logistical hurdles. Travel for fetal echocardiography or specialist review may require long flights or temporary relocation closer to a tertiary service, a reality that has prompted investment in outreach clinics and Aboriginal community-controlled health services. Language and cultural safety are increasingly embedded in services catering to the many Australian families who speak languages other than English at home, with interpreter support and bilingual midwives now standard in major public hospitals.

Detection, monitoring, and treatment decisions

Early identification begins with a careful history and antibody testing. Women known to carry anti-SSA/Ro or anti-SSB/La are usually offered fetal echocardiography between 16 and 26 weeks, with repeat surveillance if earlier scans are reassuring. In Graves disease, maternal TSH-receptor antibody measurement late in pregnancy helps predict neonatal thyrotoxicosis, and cord blood sampling may be considered at delivery in high-risk scenarios. Platelet counts, liver enzymes, and complement levels guide decision-making in lupus, particularly when active nephritis is suspected.

Therapeutic choices aim to suppress pathogenic antibody production, reduce inflammation, or, where possible, accelerate antibody clearance. Hydroxychloroquine has become a mainstay for anti-SSA-positive mothers because it lowers the risk of recurrent cardiac neonatal lupus. Corticosteroids such as dexamethasone are reserved for specific situations such as emerging heart block. Intravenous immunoglobulin and plasma exchange have a role in severe thrombocytopenia or myasthenic crisis. Decisions are always individualised, balancing fetal benefit against maternal side effects, and they often unfold within a coordinated clinic rather than in isolation.

After birth, paediatric teams take over. A neonate born to a mother with significant autoantibodies may be admitted for observation, baseline blood work, or cardiac monitoring. Practical steps include checking the neonatal platelet count in suspected immune thrombocytopenia, evaluating thyroid function when maternal TSH-receptor antibodies were elevated, and watching for feeding difficulties or ptosis in babies exposed to anti-AChR antibodies. Education for parents, including reassurance when findings are expected to resolve, supports attachment and reduces anxiety during what can be a worrying transition home.

Broader neonatal infection considerations sometimes overlap with this picture, and clinical teams increasingly draw on shared learning resources. An article reviewing neonatal candidiasis risk factors examines how immune dysregulation and intensive care exposures intersect, a useful companion read for clinicians balancing infection risk with immunosuppressive therapies.

Looking ahead in maternal-fetal immunology

Research is moving quickly. Newer biologics designed to interfere with FcRn, the same receptor that ferries IgG across the placenta, are being trialled in autoimmune disease and may eventually reshape pregnancy planning. Meanwhile, registries such as the Australian Pregnancy Register for Inflammatory Arthritis and international consortia continue to gather safety data on medications used during conception and gestation. Predictive algorithms that combine antibody titres, fetal heart rate patterns, and ultrasound findings are gradually refining personalised risk scores.

For families, the practical takeaway is that careful planning, coordinated care, and open conversations with the treating team can substantially improve outcomes. The perinatal community in Australia, including midwives, obstetric physicians, rheumatologists, and neonatologists, has built a strong collaborative culture, and ongoing education through congresses, workshops, and digital platforms keeps that knowledge current. Strengthening the link between adult rheumatology and neonatal follow-up is one of the most meaningful gains of the past decade.

Practical recommendations for clinicians and expectant parents

• Establish a multidisciplinary plan early in pregnancy whenever a mother carries antibodies known to affect the fetus, including cardiology, haematology, and neonatology input where relevant.
• Schedule serial fetal echocardiography for anti-SSA/Ro and anti-SSB/La positive pregnancies, typically between 16 and 26 weeks and again later if findings change.
• Review medications in the preconception phase, aiming for disease stability on agents with the best pregnancy safety profiles, and document shared decisions in the antenatal record.
• Arrange structured neonatal follow-up after birth, with clear thresholds for blood tests, imaging, and readmission if the infant develops concerning signs at home.
• Connect families with peer support networks and culturally appropriate counselling, recognising the emotional weight of autoimmune disease during pregnancy.

Families and clinicians who want to deepen their understanding of perinatal immunology, neonatal infection, and maternal-fetal care can revisit the scientific materials and recorded sessions shared through the FAOPS 2020 platform, where the congress's educational mission continues despite the 2020 cancellation.